Aytu Biopharma (AYTU) Assets Average (2016 - 2025)
Aytu Biopharma (AYTU) has disclosed Assets Average for 14 consecutive years, with $123.5 million as the latest value for Q4 2025.
- Quarterly Assets Average rose 6.43% to $123.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $123.5 million through Dec 2025, up 6.43% year-over-year, with the annual reading at $121.1 million for FY2025, 4.83% down from the prior year.
- Assets Average for Q4 2025 was $123.5 million at Aytu Biopharma, down from $124.6 million in the prior quarter.
- The five-year high for Assets Average was $246.7 million in Q3 2021, with the low at $116.0 million in Q4 2024.
- Average Assets Average over 5 years is $146.9 million, with a median of $133.4 million recorded in 2023.
- The sharpest move saw Assets Average skyrocketed 67.5% in 2021, then crashed 41.71% in 2022.
- Over 5 years, Assets Average stood at $225.8 million in 2021, then crashed by 35.46% to $145.7 million in 2022, then decreased by 9.37% to $132.1 million in 2023, then fell by 12.14% to $116.0 million in 2024, then increased by 6.43% to $123.5 million in 2025.
- According to Business Quant data, Assets Average over the past three periods came in at $123.5 million, $124.6 million, and $124.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.